CIZ.L
Cizzle Biotechnology Holdings Plc [CIZ.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CIZ.L Stock Summary
Top 10 Correlated ETFs
CIZ.L
Top 10 Correlated Stocks
CIZ.L
In the News
CIZ.L Financial details
Company Rating
Neutral
Market Cap
6.94M
Income
-953.48K
Revenue
0
Book val./share
0.01
Cash/share
0
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
28 Jun 2024
P/E
-7.63
Forward P/E
-
PEG
0.93
P/S
-
P/B
2.64
P/C
-
P/FCF
-9.97
Quick Ratio
3.3
Current Ratio
4.86
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-87.3%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-17.48%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
100%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-33%
ROE
-51%
ROC
-0.36%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.675-3.8
52W High
-41.33%
52W Low
+76%
RSI
37
Rel Volume
0.42
Avg Volume
1.92M
Volume
809.63K
Perf Week
0.57%
Perf Month
-20%
Perf Quarter
-12%
Perf Half Y
-12%
-
-
-
-
Beta
0.353
-
-
Volatility
0.02%, 0.26%
Prev Close
0%
Price
1.76
Change
1.73%
CIZ.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.01 | 0 | -0.01 | -0.02 | 0 | |
| Operating cash flow per share | 0 | 0 | -0.01 | -0.01 | 0 | |
| Free cash flow per share | 0 | 0 | -0.01 | -0.01 | 0 | |
| Cash per share | 0 | 0 | 0 | 0.01 | 0 | |
| Book value per share | 0 | 0 | 0 | 0.01 | 0.01 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0.01 | 0.01 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 23.76M | 1.7M | 2.33M | 4.82M | 4.22M | |
| Enterprise value | 23.76M | 1.69M | 2.24M | 3.94M | 3.75M | |
| P/E ratio | -11.55 | -78.53 | -7.6 | -1.23 | -4.63 | |
| Price to sales ratio | 321.09 | 0 | 0 | 0 | 0 | |
| POCF ratio | -46.32 | -241.04 | -7.91 | -4.77 | -4.84 | |
| PFCF ratio | -34.49 | -241.04 | -7.91 | -3.98 | -4.84 | |
| P/B Ratio | -101.11 | 257.07 | 72.71 | 5.14 | 1.6 | |
| PTB ratio | -101.11 | 257.07 | 72.71 | 5.14 | 1.6 | |
| EV to sales | 321.04 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -39.07 | -77.93 | -14.75 | 1.75 | -3.89 | |
| EV to operating cash flow | -46.31 | -239.22 | -7.63 | -3.91 | -4.3 | |
| EV to free cash flow | -34.48 | -239.22 | -7.63 | -3.26 | -4.3 | |
| Earnings yield | -0.09 | -0.01 | -0.13 | -0.81 | -0.22 | |
| Free cash flow yield | -0.03 | 0 | -0.13 | -0.25 | -0.21 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0.01 | 0.59 | 0.55 | -0.39 | 0.5 | |
| Current ratio | 0.29 | 1.67 | 1.55 | 4.38 | 4.86 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.24 | 0.33 | 0.96 | 0.25 | 0.91 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 17.99 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.17 | 0.75 | |
| Capex to operating cash flow | 0.34 | 0 | 0 | 0.2 | 0 | |
| Capex to revenue | -2.38 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.28 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.01 | 0 | 0.02 | 0.06 | 0.03 | |
| ROIC | 6.87 | -3.27 | -7.16 | 2.39 | -0.35 | |
| Return on tangible assets | -21.43 | -1.32 | -3.4 | -4.11 | -1.29 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | -235K | 6.63K | 32K | 737K | 560K | |
| Tangible asset value | -235K | 6.63K | 32K | 737K | 560K | |
| Net current asset value | -235K | 6.63K | 32K | 737K | 560K | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 15.5K | 18.5K | 43K | 153.5K | |
| Average payables | 547.5K | 78.47K | 11.47K | 66.5K | 76K | |
| Average inventory | 380.5K | -13.67K | -13.67K | -41.5 | -153.5 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 1.96K | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.19 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 8.75 | -3.27 | -9.56 | -4.18 | -0.35 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 3.94M | 5.44K | 4.46M | 11.66K | 6.09M | |
| Enterprise value | 3.5M | 4.96K | 3.98M | 11.21K | 5.63M | |
| P/E ratio | -2.53 | -5.21 | -2.14 | -13.53 | -3.53 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -9.15 | -24.66 | -10.12 | -71.33 | -18.61 | |
| PFCF ratio | -9.15 | -24.66 | -10.12 | -71.33 | -18.61 | |
| P/B Ratio | 1.58 | 2.06 | 1.69 | 4.44 | 2.32 | |
| PTB ratio | 1.58 | 2.06 | 1.69 | 4.44 | 2.32 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -8.43 | 81.3 | -7.27 | -355.93 | -12.33 | |
| EV to operating cash flow | -8.12 | -22.49 | -9.03 | -68.57 | -17.23 | |
| EV to free cash flow | -8.12 | -22.49 | -9.03 | -68.57 | -17.23 | |
| Earnings yield | -0.1 | -0.05 | -0.12 | -0.02 | -0.07 | |
| Free cash flow yield | -0.11 | -0.04 | -0.1 | -0.01 | -0.05 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 1.07 | -7.84 | 0.87 | 14.32 | 0.99 | |
| Current ratio | 4.66 | 4.86 | 4.86 | 5.18 | 5.18 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 1.11 | 0.84 | 0.84 | 0.76 | 0.76 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.8 | 0.75 | 0.75 | 0.76 | 0.76 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | |
| ROIC | -0.16 | -0.12 | -0.2 | -0.07 | -0.16 | |
| Return on tangible assets | -0.73 | -0.37 | -0.74 | -0.32 | -0.64 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | 417K | 560 | 560K | 544 | 544K | |
| Tangible asset value | 417K | 560 | 560K | 544 | 544K | |
| Net current asset value | 417K | 560 | 560K | 544 | 544K | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 43.5K | 113.5K | 113.5K | 111.5K | |
| Average payables | 0 | 57.02K | 20.52K | 20.57K | 65.07K | |
| Average inventory | 0 | -43.5K | -113.5 | -113.5 | -111.5 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.16 | -0.1 | -0.2 | -0.08 | -0.16 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CIZ.L Frequently Asked Questions
What is Cizzle Biotechnology Holdings Plc stock symbol ?
Cizzle Biotechnology Holdings Plc is a GB stock and trading under the symbol CIZ.L
What is Cizzle Biotechnology Holdings Plc stock quote today ?
Cizzle Biotechnology Holdings Plc stock price is $1.76 today.
Is Cizzle Biotechnology Holdings Plc stock public?
Yes, Cizzle Biotechnology Holdings Plc is a publicly traded company.
Company Profile
- Volume Average 1.92M
- Market Capitalization 6.94M
- Employee 4
- CEO Mr. Allan John Syms
- Headquarters London,GB
- IPO Date 2021-05-14
-
Website
https://www.cizzlebiotechnology.com 
Cizzle Biotechnology Holdings Plc engages in development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
